Research programme: antibacterials - MerLion/Vernalis

Drug Profile

Research programme: antibacterials - MerLion/Vernalis

Alternative Names: Antibacterials research programme - MerLion/Vernalis

Latest Information Update: 06 Feb 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MerLion Pharmaceuticals; Vernalis
  • Class
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 14 Jan 2005 Discontinued - Preclinical for Bacterial infections in Singapore (unspecified route)
  • 14 Jan 2005 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
  • 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top